PRGO:NYE-Perrigo Company plc (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 30.8

Change

+0.86 (+2.87)%

Market Cap

USD 12.59B

Volume

1.17M

Analyst Target

USD 57.88
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Perrigo Co PLC develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-19 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+8.73 (+5.51%)

USD 66.94B
TAK Takeda Pharmaceutical Co Ltd A..

+0.08 (+0.61%)

USD 41.54B
HLN Haleon plc

-0.03 (-0.36%)

USD 37.53B
TEVA Teva Pharma Industries Ltd ADR

+0.10 (+0.72%)

USD 15.97B
RDY Dr. Reddy’s Laboratories Ltd..

+0.80 (+1.08%)

USD 11.85B
CTLT Catalent Inc

+0.34 (+0.61%)

USD 10.04B
ELAN Elanco Animal Health

+0.32 (+2.43%)

USD 6.40B
HYPMY Hypera SA

+0.37 (+6.89%)

USD 3.81B
PBH Prestige Brand Holdings Inc

+0.14 (+0.20%)

USD 3.43B
EVT Eaton Vance Tax Advantaged Div..

+0.16 (+0.71%)

USD 3.26B

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
M7ES:XETRA HANetf ICAV - Sprott Ener.. 4.48 % 0.00 %

-0.01 (-0.22%)

USD 3.26M
ION Proshares S&P Global Core.. 4.06 % 0.00 %

+0.75 (+-0.22%)

USD 2.24M
RNMC First Trust Mid Cap US Eq.. 1.06 % 0.60 %

+0.26 (+-0.22%)

USD 0.02B
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.20 (+-0.22%)

USD 0.01B
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.46 (+-0.22%)

USD 0.21B
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
WSRD:CA Wealthsimple Developed Ma.. 0.00 % 0.00 %

+0.10 (+-0.22%)

CAD 0.60B
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.29% 44% F 29% F
Dividend Return 0.86% 50% F 45% F
Total Return -3.43% 50% F 29% F
Trailing 12 Months  
Capital Gain -15.48% 38% F 16% F
Dividend Return 3.00% 80% B- 45% F
Total Return -12.47% 38% F 16% F
Trailing 5 Years  
Capital Gain -36.91% 46% F 16% F
Dividend Return 10.03% 75% C 39% F
Total Return -26.88% 54% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain -9.97% 38% F 10% F
Dividend Return -7.72% 38% F 9% A-
Total Return 2.25% 80% B- 51% F
Risk Return Profile  
Volatility (Standard Deviation) 10.69% 100% F 80% B-
Risk Adjusted Return -72.19% 6% D- 4% F
Market Capitalization 12.59B 56% F 74% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 380.75 7% 2%
Price/Book Ratio 0.89 75% 77%
Price / Cash Flow Ratio 10.49 53% 36%
Price/Free Cash Flow Ratio 14.43 31% 27%
Management Effectiveness  
Return on Equity -0.09% 69% 29%
Return on Invested Capital 1.75% 40% 30%
Return on Assets 1.64% 50% 40%
Debt to Equity Ratio 76.19% 64% 46%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.